Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Who is partnered with LABS now?
View:
Post by subaru1i on Jan 08, 2024 10:06am

Who is partnered with LABS now?

(Reuters) -Johnson & Johnson said on Monday it had agreed to buy drug developer Ambrx Biopharma for $2 billion to gain access to its portfolio of targeted cancer therapies.
 
J&J will pay $28 per share of Ambrx, which represents a premium of about 105% to the stock's last close.

Ambrx is developing therapies that belong to the class of drugs called antibody drug conjugates (ADC), which are described by researchers as "guided missiles" to target cancer cells and minimize damage to healthy tissue.
 
J&J's acquisition is the latest deal announced in the space. In November, AbbVie said it would buy ADC-developer ImmunoGen for $10.1 billion in cash.


WHAT'S THE PAYLOAD FOR J&J OR PFIZER VIA SEAGEN? 

Ya :-)
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities